아시아 태평양 탄저병 치료 시장, 유형별( 피부 탄저병 , 폐 탄저병 및 장 탄저병), 투여 경로(경구, 비경구 및 기타), 최종 사용자(정부 기관, 병원, 학술 및 연구 기관 및 기타) - 업계 동향 및 2029년까지의 전망.
아시아 태평양 탄저균 치료 시장 분석 및 통찰력
아시아 태평양 탄저균 치료 시장은 박테리아 감염 발생률 증가 , 연구 자금 증가, 탄저균 치료 및 파이프라인 제품에 대한 새로운 치료법 개발과 같은 요인에 의해 주도되고 있으며, 수요도 증가하고 연구 개발에 대한 투자 증가로 시장이 성장하고 있습니다. 현재 선진국과 신흥국에서 의료비 지출이 증가하여 제조업체가 새롭고 혁신적인 제품을 개발할 수 있는 경쟁 우위를 확보할 것으로 예상됩니다.
전 세계적으로 탄저병에 걸린 사람의 수가 증가하면서 탄저병 치료 시장이 성장하는 주요 요인 중 하나가 되었습니다. 연구자들이 새로운 개입법을 개발하기 위한 재정 지원이 증가하고, 민간인과 군대 사이에서 탄저균에 노출될 위험이 증가하면서 시장 성장이 가속화되었습니다. 연구 개발 프로그램의 수가 증가하고, 혁신적이고 효과적인 치료를 위한 새로운 개발을 촉진하기 위한 공공-민간 파트너십이 증가하면서 시장에 더 많은 영향을 미쳤습니다. 그러나 치료 및 시술과 관련된 높은 비용과 제품 승인을 위한 엄격한 정부 규정이 탄저병 치료 시장 성장을 방해할 것으로 예상됩니다.
아시아 태평양 탄저균 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
아시아 태평양 탄저균 치료 시장은 긍정적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 아시아 태평양 탄저균 치료 시장이 2022년에서 2029년까지의 예측 기간 동안 7.0%의 CAGR로 성장할 것이라고 분석합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others),End User (Government Organization, Hospitals, Academic and Research Institutes, and Others) Industry Trends and Forecast to 2029 |
|
Countries Covered |
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific |
|
Market Players Covered |
Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Lupin, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., GC Biopharma, corp., among others |
Asia-Pacific Anthrax Treatment Market Dynamics
Market Definition
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Drivers
- Increasing Prevalence of Anthrax Infections
The incidence of bacterial infections is increasing worldwide. Anthrax is a bacterial infection caused by Bacillus anthracis which is an aerobic, gram-positive spore-forming bacterium. Depending on the route of entry of B. anthracis spores, it occurs primarily as a cutaneous, pulmonary, or gastrointestinal infection. A characteristic black, crusty spot develops on the affected skin area later and, after a few weeks, begins to loosen and ultimately falls off, leaving a scar. The course of these events is so characteristic that the diagnosis is not often missed by physicians familiar with the disease, even though it is rare. Pulmonary anthrax is the most lethal of the three types of anthrax in which, the spores once inhaled germinate within the tracheobronchial lymph nodes and multiply. Anthrax is a harmful disease that affects both humans and animals. It is a life-threatening infection caused by Bacillus anthracis. Thus, this increasing incidence and prevalence of anthrax infections has developed a need of more diagnostic approaches with increased sensitivity that can detect infection in low volume.
The increase in the number of people suffering from anthrax across the globe acts as one of the major factors driving the growth of anthrax treatment market. The increase in the financial support to the researchers for developing novel intervention, and rise in threat of exposure to Bacillus anthracis among civilian populations and military forces accelerate the market growth. The increase in the number of research and development programs, and rise in public-private partnerships for facilitating novel developments for the innovative and effective treatment further influence the market.
- Increasing Research Funding and the development of novel therapies for anthrax treatment population
Research and development is a prerequisite in order to modify the procedure intended to treat different kinds of patients. The demand of anthrax treatment is increasing worldwide involving every country. This is why the companies are continuously focusing towards research and development in order to achieve success in providing effective treatment to patients. In these recent years many diagnostic approaches have come forward to take diagnosis to new steps, and many are being made to detect even the lowest volume of parasite in human body.
These new approaches in diagnosis will take the market forward. With the increase in research funding and the development of novel therapies for the treatment of anthrax. There are several novel and pre-existing antibiotics, as well as toxin inhibitors that have shown increasing promise that targets both bacterial growth as well as toxin production for effectively work against anthrax bacterium.
As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Asia-Pacific anthrax treatment market growth
Opportunities
- Rising product launch
Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.
Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Asia-Pacific market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.
Restraints/Challenges
- High cost of treatment
The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.
Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the Asia-Pacific anthrax treatment market growth.
Recent Development
- In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
- In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.
Asia-Pacific Anthrax Treatment Market Segmentation
Asia-Pacific anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of type, the Asia-Pacific anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.
Route of Administration
- Cutaneous Anthrax
- Pulmonary Anthrax
- Intestinal Anthrax
On the basis of route of administration, Asia-Pacific anthrax treatment market is segmented into oral, parenteral and others.
End User
- Government Organization
- Hospitals
- Academic and Research Institutes,
- Others
On the basis of end user, Asia-Pacific anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.
Anthrax Treatment Market Regional Analysis/Insights
Asia-Pacific anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.
The countries covered in the anthrax treatment report are Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines and Rest of Asia-Pacific.
중국은 개발 도상국의 기술 진보가 빠르게 진행됨에 따라 우위를 점할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 탄저균 치료 시장 점유율 분석
아시아 태평양 탄저균 치료 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 탄저균 치료 시장에 대한 회사의 초점과만 관련이 있습니다.
시장의 주요 기업으로는 Alembic Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Zydus Group, Bayer AG, Pfizer Inc., EMERGENT, Sanofi, Lupin, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ARISTO Pharmaceuticals Private Limited, INDOCO REMEDIES LTD., GC Biopharma, corp. 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC ANTHRAX TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 DEMOGRAPHIC TRENDS-
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-
4.4.1 INCIDENCE
4.4.2 DEVELOPED COUNTRIES-
4.4.3 DEVELOPING COUNTRIES-
4.5 PATIENT ENROLMENT STRATEGIES-
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-
4.7 CURRENT STATE OF ANTHRAX VACCINES
4.8 ASIA PACIFIC ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.
4.9 ASIA PACIFIC ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.
6 ASIA PACIFIC ANTHRAX TREATMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT
7.2.2 FALSE DATA INTERPRETATION
7.3 OPPORTUNITIES
7.3.1 RISING PRODUCT LAUNCHES
7.3.2 RISING GOVERNMENT INITIATIVES
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
7.4 CHALLENGES
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION
7.4.2 LACK OF SKILLED PROFESSIONALS
8 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CUTANEOUS ANTHRAX
8.2.1 ANTIBIOTICS
8.2.1.1 BY DRUGS
8.2.1.1.1 CIPROFLOXACIN
8.2.1.1.2 LEVOFLOXACIN
8.2.1.1.3 DOXYCYCLINE
8.2.1.1.4 AMPICILLIN
8.2.1.1.5 OTHERS
8.2.1.2 BY PRODUCT TYPES
8.2.1.2.1 GENERICS
8.2.1.2.2 BRANDED
8.2.1.2.2.1 CIPRO
8.2.1.2.2.2 LEVO
8.2.1.2.2.3 DOXY
8.2.1.2.2.4 AMPICI
8.2.1.2.2.5 OTHERS
8.2.2 ANTITOXINS
8.2.2.1 RAXIBACUMAB
8.2.2.2 OBILTOXAXIMAB (ANTHIM)
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.2.2.4 OTHERS
8.2.3 VACCINES
8.2.3.1 RAXIBACUMAB
8.2.4 SURGERY
8.3 PULMONARY ANTHRAX
8.3.1 ANTIBIOTICS
8.3.1.1 BY DRUGS
8.3.1.1.1 CIPROFLOXACIN
8.3.1.1.2 LEVOFLOXACIN
8.3.1.1.3 DOXYCYCLINE
8.3.1.1.4 AMPICILLIN
8.3.1.1.5 OTHERS
8.3.1.2 BY PRODUCT TYPES
8.3.1.2.1 GENERICS
8.3.1.2.2 BRANDED
8.3.1.2.2.1 CIPRO
8.3.1.2.2.2 LEVO
8.3.1.2.2.3 DOXY
8.3.1.2.2.4 AMPICI
8.3.1.2.2.5 OTHERS
8.3.2 ANTITOXINS
8.3.2.1 RAXIBACUMAB
8.3.2.2 OBILTOXAXIMAB (ANTHIM)
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.3.2.4 OTHERS
8.3.3 VACCINES
8.3.3.1 RAXIBACUMAB
8.3.3.2 SURGERY
8.4 INTESTINAL ANTHRAX
8.4.1 ANTIBIOTICS
8.4.1.1 BY DRUGS
8.4.1.1.1 CIPROFLOXACIN
8.4.1.1.2 LEVOFLOXACIN
8.4.1.1.3 DOXYCYCLINE
8.4.1.1.4 AMPICILLIN
8.4.1.1.5 OTHERS
8.4.1.2 BY PRODUCT TYPES
8.4.1.2.1 GENERICS
8.4.1.2.2 BRANDED
8.4.1.2.2.1 CIPRO
8.4.1.2.2.2 LEVO
8.4.1.2.2.3 DOXY
8.4.1.2.2.4 AMPICI
8.4.1.2.2.5 OTHERS
8.4.2 ANTITOXINS
8.4.2.1 RAXIBACUMAB
8.4.2.2 OBILTOXAXIMAB (ANTHIM)
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)
8.4.2.4 OTHERS
8.4.3 VACCINES
8.4.3.1 RAXIBACUMAB
8.4.3.2 SURGERY
9 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 PARENTERAL
9.3 ORAL
9.4 OTHERS
10 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY END USER
10.1 OVERVIEW
10.2 GOVERNMENT ORGANIZATION
10.3 HOSPITALS
10.4 ACADEMIC AND RESEARCH
10.5 OTHERS
11 ASIA PACIFIC VIRTUAL REALITY MARKET, BY GEOGRAPHY
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 SOUTH KOREA
11.1.4 INDIA
11.1.5 AUSTRALIA
11.1.6 SINGAPORE
11.1.7 THAILAND
11.1.8 MALAYSIA
11.1.9 INDONESIA
11.1.10 PHILIPPINES
11.1.11 REST OF ASIA-PACIFIC
12 ASIA PACIFIC ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 BAYER AG
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ALEMBIC PHARMACEUTICALS LIMITED
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 ALTIMMUNE
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWILLOW BIOLOGICS.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 DEINOVE
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EMERGENT
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 ELUSYS THERAPEUTICS INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GC BIOPHARMA CORP.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 INDOCO REMEDIES LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED BIOTHERAPEUTICS, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUPIN.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PARATEK PHARMACEUTICALS, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 PORTON BIOPHARMA
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENTS
14.19 SOLIGENIX
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-
TABLE 2 VACCINES IN DEVELOPMENT
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-
TABLE 5 RECENT M&A IN ANTHRAX MARKET-
TABLE 6 ANTIBIOTICS MEDICINES
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 8 ASIA PACIFIC ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA PACIFIC ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 48 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 49 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 52 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 53 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 55 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 56 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 59 ASIA-PACIFIC PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 67 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 68 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 70 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 71 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 73 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 74 ASIA-PACIFIC INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 78 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 82 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 85 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 88 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 89 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 91 CHINA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 CHINA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 96 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 99 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 101 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 103 CHINA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 107 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 110 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 114 CHINA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 118 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 121 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 123 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 125 CHINA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 126 CHINA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 127 JAPAN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 JAPAN CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 132 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 135 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 137 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 139 JAPAN PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 143 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 146 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 148 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 150 JAPAN INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 154 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 157 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 161 JAPAN ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 162 JAPAN ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 163 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 SOUTH KOREA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 168 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 171 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 173 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 175 SOUTH KOREA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 182 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 184 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 186 SOUTH KOREA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 190 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 193 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 195 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 197 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 198 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 199 INDIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 INDIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 204 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 207 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 209 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 211 INDIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 213 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 215 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 218 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 220 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 222 INDIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 226 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 229 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 231 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 233 INDIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 234 INDIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 235 AUSTRALIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 AUSTRALIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 240 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 241 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 244 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 246 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 248 AUSTRALIA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 249 AUSTRALIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 252 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 253 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 254 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 255 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 256 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 258 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 260 AUSTRALIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 264 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 266 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 267 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 268 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 269 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 270 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 271 AUSTRALIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 272 AUSTRALIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 273 SINGAPORE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 SINGAPORE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 277 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 278 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 279 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 280 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 281 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 282 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 283 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 284 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 285 SINGAPORE PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 289 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 292 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 294 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 295 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 296 SINGAPORE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 297 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 298 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 300 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 301 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 302 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 303 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 304 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 305 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 307 SINGAPORE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 308 SINGAPORE ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 309 THAILAND ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 310 THAILAND CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 311 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 312 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 313 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 314 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 315 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 316 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 317 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 319 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 320 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 321 THAILAND PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 322 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 323 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 324 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 325 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 326 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 327 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 328 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 329 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 330 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 332 THAILAND INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 333 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 334 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 336 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 337 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 338 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 339 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 340 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 341 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 342 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 343 THAILAND ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 344 THAILAND ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 345 MALAYSIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 346 MALAYSIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 347 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 348 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 349 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 350 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 351 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 352 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 353 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 354 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 355 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 356 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 357 MALAYSIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 358 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 359 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 360 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 361 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 362 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 364 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 365 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 366 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 367 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 368 MALAYSIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 369 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 371 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 372 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 373 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 374 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 375 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 376 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 377 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 378 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 379 MALAYSIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 380 MALAYSIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 381 INDONESIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 382 INDONESIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 383 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 384 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 386 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 387 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 388 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 389 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 390 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 391 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 392 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 393 INDONESIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 394 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 395 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 396 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 397 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 398 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 400 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 401 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 402 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 403 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 404 INDONESIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 405 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 406 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 407 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 408 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 409 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 410 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 411 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 412 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 413 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 414 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 415 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 416 INDONESIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 417 INDONESIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 418 PHILIPPINES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 419 PHILIPPINES CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 420 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 421 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 422 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 423 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 424 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 425 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 426 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 427 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 428 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 429 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 430 PHILIPPINES PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 431 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 432 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 433 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 434 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 435 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 436 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 437 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 438 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 439 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 440 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 441 PHILIPPINES INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 442 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 443 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 444 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 445 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 446 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 447 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 448 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 449 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 450 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 451 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 452 PHILIPPINES ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 453 PHILIPPINES ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 454 REST OF ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 ASIA PACIFIC ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC ANTHRAX TREATMENT MARKET: SEGMENTATION
FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE ASIA PACIFIC ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ANTHRAX TREATMENT MARKET IN 2022 & 2029
FIGURE 14 ASIA PACIFIC DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-
FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-
FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-
FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).
FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).
FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC ANTHRAX TREATMENT MARKET
FIGURE 21 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, 2021
FIGURE 22 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 23 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)
FIGURE 24 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 26 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 27 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 28 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, 2021
FIGURE 30 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)
FIGURE 32 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 34 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 35 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 36 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 37 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 38 ASIA PACIFIC ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
